Please login to the form below

Not currently logged in

China to relax pricing curbs from June

Reports suggest medicine sales could reach $185bn in the region by 2018

Shire enters research partnership for rare eye disease

Shire BasingstokeWill work with Foundation Fighting Blindness on treatment for adRP

Cancer drug spend tops $100bn in 2014

Roche Avastin bevacizumab cancerBut payers are starting to bulk at increasing prices

Baxter and Merrimack file pancreatic cancer drug in EU

Baxter buildingMM-398 is thought to help direct the active drug into tumours

Prescribing costs jump in England

Doctor writing prescription for medicinesNew report finds that asthma and diabetes drugs the most costly to the NHS

FDA clears Advair follow up Breo for asthma

GSK GlaxoSmithKline houseBut respiratory drug given the thumbs up for adults only

New-look Directory from PMGroup launches

Fresh design and updated content shapes the publication’s evolution

Prostate cancer treatment market to treble to £8.2bn by 2023

Astellas Xtandi enzalutamideBut GlobalData predict growth could be hampered by patent loss for Zytiga

Eylea growth closes the gap with Lucentis

Bayer Eylea aflibercept wet AMDBayer/Regeneron’s drug eye disease drug set for blockbuster status

More money for the NHS – but is this the answer?

Politicians opening their pre-election cheque books can’t put the UK’s health service where it needs to be – but pharma could have a major role to play

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
GEM Group

GEM Group a leading healthcare professional media buyer based in the UK working for clients across the globe....

Latest intelligence

Webinar recording: The storytelling method that works for e-detailing
If you can involve healthcare professionals in a story, they will be more open to your arguments....
Paul Mannu of Cello Health Insight says that politicians opening their pre-election cheque books can’t put the NHS where it needs to be – but pharma can play a major...
Medius Deal Watch
Pharma deals in February 2015
Pfizer and Valeant led the way during a respectable, if not record-breaking, month for mergers, acquisitions and collaborations...